OmniAb, Inc. filed a Form D with the Securities and Exchange Commission on 2025-09-10.
OmniAb, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 10, 2025. OmniAb, Inc. trades on Nasdaq as OABI; it was formerly Avista Public Acquisition Corp. II. The filing reports $30M sold. Its industry group is Biotechnology. It names Matthew Foehr (Executive Officer, Director), Kurt Gustafson (Executive Officer), Charles Berkman (Executive Officer) (SEC Form D, September 10, 2025).
In its own words: “As a leading-edge antibody discovery company, OmniAb brings a high level of expertise and innovation.” (omniab.com, checked November 1, 2026)
Is this your company?
Sell to companies like OmniAb, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns OmniAb, Inc.
Free to see. No signup.
More on the people and the money behind OmniAb, Inc., from the filings we hold.
Leerink Partners LLC received sales compensation on this raise and on 10 other raises we hold, nearest in date first:
Biotechnology raises by companies based in California, filed in September 2025, largest first.
Get an email when OmniAb, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when OmniAb, Inc. raises, hires or launches. No email unless you switch it on.
Watch OmniAb, Inc. →Get the full cited report on OmniAb, Inc.
What the filing shows about OmniAb, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on OmniAb, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives OmniAb, Inc.'s address as 5980 Horton Street, Suite 600, Emeryville, CA 94608.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
OmniAb, Inc. is a registered filer with the SEC (CIK 1846253) and has filed since 2025-09-10. 1 filing is on record, the latest on 2025-09-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
OmniAb, Inc.'s Form D of 2025-09-10 names Matthew Foehr, Kurt Gustafson, Charles Berkman and 6 more as its officers, directors or promoters.
Its new offerings report $30M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Matthew Foehr is named as Executive Officer and Director on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
Kurt Gustafson is named as Executive Officer on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
Charles Berkman is named as Executive Officer on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
John Higgins is named as Director on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
Jennifer Cochran is named as Director on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
Carolyn Bertozzi is named as Director on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
Steve Love is named as Director on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
Steve Crouse is named as Director on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
Philip Gotwals is named as Director on the Form D that OmniAb, Inc. filed with the SEC on 10 September 2025, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2025-09-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about OmniAb, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on OmniAb, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OmniAb, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist OmniAb, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind OmniAb, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for OmniAb, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/omniab-inc-form-d-25000001